La chaîne d'options affiche les données clés des options sur actions de Organovo Holdings à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Organovo Holdings..

Organovo Holdings (NASDAQ:ONVO) Stock, Chaîne d'Options

Organovo Holdings

Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Organovo Holdings Inc

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday.
The Dow traded up 0.46% to 43,661.51 while the NASDAQ fell 1.07% to 19,080.23. The S&amp;P 500 also fell, dropping, 0.29% to 5,965.92.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43909562/top-2-industrials-stocks-that-are-set-to-fly-this-quarter">Top 2 Industrials Stocks That Are Set To Fly This Quarter</a>
Leading and Lagging Sectors Consumer staples shares jumped by 1.3% on Tuesday.
In trading on Tuesday, energy shares fell by 1.3%.
Top Headline
Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) shares gained around 2.5% on Tuesday following better-than-expected quarterly results.
The company reported fourth-quarter adjusted earnings per share of 58 cents, beating the street view of 57 cents. Quarterly sales of $4.07 billion (+5.2% year over year), outpaced the analyst consensus estimate of $4.02 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares shot up 217% to $1.19 after the company announced that Eli Lilly is set to acquire its FXR program, including FXR314.</li>
<li>Shares of Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>)got a boost, surging 84% to $3.2950 after the company announced it will integrate DeepSeek to drive AI-based education innovation and long-term growth strategies.</li>
<li>AdaptHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) shares were also up, gaining 24% to $10.57 after the company reported better-than-expected fourth-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares dropped 30% to $9.11 after the company reported worse-than-expected quarterly financial results.</li>
<li>Shares of Hims &amp; Hers Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) were down 22% to $40.02 after the company reported fourth-quarter financial results.</li>
<li>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) was down, falling 19% to $70.52 after the company issued FY25 EPS below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $69.02 while gold traded down 1.3% at $2,924.50.
Silver traded down 2% to $31.95 on Tuesday, while copper rose 0.7% to $4.5470.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.15%, Germany's DAX 40 fell 0.07% and France's CAC 40 fell 0.49%. Spain's IBEX 35 Index rose 0.80%, while London's FTSE 100 rose 0.11%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei falling 1.39%, China's Shanghai Composite Index falling 0.80%, Hong Kong's Hang Seng Index dipping 1.32% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>The Dallas Fed&#8217;s general business activity index for Texas's service sector fell by 2.8 points to a reading of 4.6 in February.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose by 4.5% year-over-year in December compared to 4.3% in the previous month.</li>
<li>The FHFA house prices index increased by 0.4% in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AHCO

BTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ONVO

WAFU

Dow Surges 200 Points; Keurig Dr Pepper Posts Upbeat Earnings

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday.
The Dow traded down 0.14% to 43,401.71 while the NASDAQ fell 1.46% to 19,005.00. The S&amp;P 500 also fell, dropping, 0.77% to 5,936.91.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43909562/top-2-industrials-stocks-that-are-set-to-fly-this-quarter">Top 2 Industrials Stocks That Are Set To Fly This Quarter</a>
Leading and Lagging Sectors Consumer staples shares jumped by 1.8% on Tuesday.
In trading on Tuesday, consumer discretionary shares fell by 1.9%.
Top Headline
Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) reported better-than-expected fourth-quarter 2024 results and provided its 2025 outlook.
HD reported fourth-quarter sales growth of 14.1% year-over-year to $39.70 billion, beating the consensus estimate of $39.14 billion. Adjusted EPS was $3.13 (+9.4% year over year), beating the consensus of $3.00.
For 2025, Home Depot said it expects total sales growth of 2% year-over-year, reaching $163.98 billion, slightly below the consensus of $164.17 billion. The company projects adjusted EPS to decline by about 2%, from $15.24 to $14.94, falling short of the $15.57 consensus estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares shot up 332% to $1.59 after the company announced that Eli Lilly is set to acquire its FXR program, including FXR314.</li>
<li>Shares of Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>)got a boost, surging 86% to $3.3241 after the company announced it will integrate DeepSeek to drive AI-based education innovation and long-term growth strategies.</li>
<li>Femto Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) shares were also up, gaining 66% to $5.85.</li>
</ul>
Equities Trading DOWN
<ul>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares dropped 41% to $3.99.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 40% to $4.0989.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) was down, falling 38% to $0.78. Connexa Sports Technologies recently announced it signed a multi-channel-network (MCN) deal to create content for TikTok in the MENA region.</li>
</ul>
Commodities In commodity news, oil traded down 2.8% to $68.74 while gold traded down 1.8% at $2,910.00.
Silver traded down 2.6% to $31.760 on Tuesday, while copper rose 0.1% to $4.5210.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX 40 fell 0.1% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index rose 0.8%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei falling 1.39%, China's Shanghai Composite Index falling 0.80%, Hong Kong's Hang Seng Index dipping 1.32% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>The Dallas Fed&#8217;s general business activity index for Texas's service sector fell by 2.8 points to a reading of 4.6 in February.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose by 4.5% year-over-year in December compared to 4.3% in the previous month.</li>
<li>The FHFA house prices index increased by 0.4% in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

FMTO

RNAZ

SXTC

Connexa Sports Technologies Inc. - Common Stock

YYAI

Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast

Organovo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares are trading higher by 198.1% to $1.12 Tuesday morning after the company announced that Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to acquire its <a href="https://www.benzinga.com/pressreleases/25/02/g43938381/organovos-fxr-program-including-fxr314-to-be-acquired-by-eli-lilly-and-company">FXR program</a>, including FXR314.
What To Know: San Diego-based biotechnology company Organovo announced that Eli Lilly will acquire its FXR program, including lead asset FXR314, aimed at treating inflammatory bowel disease. Organovo Executive Chairman Keith Murphy called the deal a major milestone, highlighting Lilly's expertise in drug development.
The agreement includes an upfront payment to Organovo, along with potential milestone payments tied to regulatory and commercial achievements. Lilly will gain full commercial and intellectual property rights to the FXR program for global development. 
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43937535/home-depot-lifts-annual-dividend-after-strong-q4-but-soft-2025-outlook-weighs-on-stock">Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ONVO has a 52-week high of $1.74 and a 52-week low of $0.32.

Why Organovo (ONVO) Stock Is Skyrocketing

Organovo Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Up 214.4%

WIIM

Organovo shares are trading higher after the company announced that Eli Lilly is set to acquire its FXR program, including FXR314.

Biotech

General

Lilly To Acquire Organovo's FXR Program, Including FXR314; Terms Not Disclosed

Management

Organovo Appoints Norman Staskey As CFO

On December 23, 2024, Hess, the Company's former President, Chief Financial Officer and Principal Financial Officer, notified the Company of his intent to resign and resigned effective December 24, 2024, from his part-time role to pursue retirement.&nbsp;
Hess's resignation is not a result of any disagreement with the Company or any matter relating to its accounting or financial policies or procedures.
 &nbsp;

Organovo Holdings Appoints Norman Staskey As President, CFO And Principal Financial Officer, Effective December 30, 2024, In Connection With Resignation Of Tomas Hess - Filing

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo Holdings shares are trading higher after the company announced it will present clinical data of FXR314 in its Phase 2 MASH study in an oral presentation sponsored by the American Association for the Study of Liver Diseases.

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.

Organovo To Present Clinical Data Of FXR314 In Phase 2 MASH In An Oral Presentation At The Liver Meeting Sponsored By The American Association For The Study Of Liver Diseases

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Aslan Pharmaceuticals Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>)</h3>
<ul>
<li>On July 17, ASLAN Pharmaceuticals announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. The company said this decision was made following a thorough review of ASLAN SG's financial situation and strategic options. The company's stock fell around 69% over the past five days and has a <a href="https://www.benzinga.com/quote/ASLN">52-week low of $0.48</a>.</li>
<li>RSI Value: 25.34</li>
<li>ASLN Price Action: Shares of Aslan Pharmaceuticals fell 37% to close at $0.70 on Wednesday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's real-time newsfeed</a> alerted to latest Aslan Pharmaceuticals news.</li>
</ul>
<h3 class="wp-block-heading">CERo Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On June 13, the company executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The company's stock fell around 33% over the past month. It <a href="https://www.benzinga.com/quote/CERO">has a 52-week low</a> of $0.16.</li>
<li>RSI Value: 20.79</li>
<li>CERO Price Action: Shares of CERo Therapeutics gained 6.2% to close at $0.21 on Wednesday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="https://pro.benzinga.com/dashboard">trend in CERO stock</a>.</li>
</ul>
<h3 class="wp-block-heading">Organovo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>)</h3>
<ul>
<li>On July 16, Organovo presented the company&#8217;s outlook and plans at Jones Trading Healthcare Conference. The company's stock dipped around 18% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/ONVO">low of $0.55</a>.</li>
<li>RSI Value: 20.53</li>
<li>ONVO Price Action: Shares of Organovo fell 5.2% to close at $0.59 on Wednesday.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in Organovo shares</a>.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39814553/jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there">Jim Cramer Says Don&#8217;t Sell Match Group: &#8216;You&#8217;ve Just Got A Very, Very Smart Investor In There</a>&#8216;</li>
</ul>

Long Ideas

Pre-Market Outlook

ASLN

CERO

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603</a>

Organovo Granted U.S. Patent #12037603: Methods for tissue fabrication

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company's lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and preclinical models. DDW2024 is being held in Washington, D.C. May 18-21, 2024.

Organovo Reports Data Demonstrating Potential For FXR314 As Combination Therapy With Tofacitinib For Inflammatory Bowel Disease Presented At Digestive Disease Week

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668</a>

Tech

Organovo Granted U.S. Patent #11982668:	Use Of Engineered Renal Tissues In Assays

Organovo Holdings shares are trading lower after the company announced the pricing of a $5.25 million public offering of 6,562,500 shares and common warrants.

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/05/38715910/applovin-stock-jumps-on-strong-q1-earnings-the-details">first-quarter financial results</a>.
The company posted revenue of $1.058 billion, versus estimates of $974.361 million. Its earnings came in at 67 cents per share, versus expectations of 55 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AppLovin shares jumped 14.8% to $85.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 60.3% to $2.71 in pre-market trading. Pop Culture reported revenue of $24 million for the six months ended Dec. 31, 2023, up from $12.75 million in the year-ago period.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) gained 36.1% to $60.87 in pre-market trading after reporting first-quarter results.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 21.6% to $4.41 in pre-market trading. Inspire Veterinary Partners recently announced a 1-for-100 reverse stock split.</li>
<li>Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 17.7% to $1.04 in today's pre-market trading.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares gained 14.3% to $1.44 in pre-market trading after the company reported a strategic partnership with a leading Hong Kong Insurance Company to enhance AI-driven customer service.</li>
<li>TuanChe Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) jumped 13% to $2.61 in pre-market trading.</li>
<li>Treasure Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 12.6% to $5.35 in pre-market trading. Treasure Global is expected to report its financial results for the third quarter of fiscal year 2024, after the closing bell on Tuesday, May 14.</li>
<li>Compass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) shares rose 12.5% to $3.69 in pre-market trading after posting first-quarter results.</li>
<li>Magnite, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) shares gained 10.6% to $9.85 in pre-market trading after the company reported first-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) fell 36.7% to $0.8487 in pre-market trading. Tivic Health Systems shares jumped around 28% on Wednesday after the company announced the final results of its pilot research study on cervical vagus nerve stimulation.</li>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares declined 35.6% to $2.70 in pre-market trading after the company reported first-quarter financial results and announced initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.</li>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares fell 28.8% to $10.40 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) fell 27.2% to $0.6969 in pre-market trading after the company priced its $5.25 million public offering of 6,562,500 common shares and common warrants at a combined price of $0.80.</li>
<li>Delta Apparel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLA#NYSE">DLA</a>) fell 23.5% to $2.15 pre-market trading following weaker-than-expected second-quarter results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares fell 20% to $4.03 in pre-market trading. Bioventus recently reported better-than-expected first-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares declined 17.4% to $49.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares fell 13.4% to $7.11 in pre-market trading after the company reported a wider-than-expected loss for its first quarter. The company sees second-quarter revenue to be between $85 million and $90 million and full-year 2024 revenue to be between $315 million and $345 million.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares declined 12.4% to $213.95 in pre-market trading after the company reported first quarter financial results.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) fell 7.4% to $357.60 pre-market trading after the company reported first quarter financial results and issued a business update.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38722280/roblox-beyond-meat-and-3-stocks-to-watch-heading-into-thursday">Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday</a>

Movers

AIXI

ARGX

BYND

CDLX

COMP

CPOP

CTMX

DUOL

EXAS

MGNI

NUKK

SEZL

TIVC

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Reported Earlier, Organovo Prices $5.25M Public Offering Of 6,562,500 Common Shares And Common Warrants At A Combined Price Of $0.80

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80 (or $0.799 per share subject to pre-funded warrants and accompanying warrant to purchase one share of common stock). &nbsp;
The common warrants will have an exercise price of&nbsp;$0.80&nbsp;per share, will be immediately exercisable upon issuance and have a term of five years after their original issuance date. The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be&nbsp;$5.25 million&nbsp;(excluding any proceeds that may be received upon the exercise of the common warrants). The offering is expected to close on or about&nbsp;May 13, 2024, subject to the satisfaction of customary closing conditions.
JonesTrading Institutional Services LLC ("Jones") is acting as the exclusive placement agent for the offering.

Offerings

Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of  6,562,500 Shares Of Common Stock  And Common Warrants At A Combined Price Of $0.80

Press Releases

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Financing

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Health Care

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Contracts

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Comments

Organovo Holdings

Organovo Holdings (ONVO) Options

Organovo Holdings (NASDAQ:ONVO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL